Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250555 | 0.88 | PDE4B (0.54) | LMNAL3MBTL1TSHRSMN1; SMN2OPRM1 | |
| SCHEMBL31724715 | 0.86 | ROCK1 (0.47) | LMNAL3MBTL1SMN1; SMN2OPRM1OPRD1 | |
| SCHEMBL4260035 | 0.86 | TSHR (0.59) | L3MBTL1TSHRSMN1; SMN2OPRM1OPRD1 | |
| SCHEMBL19406082 | 0.84 | MAOB (0.51) | LMNASMN1; SMN2OPRM1OPRD1OPRK1 | |
| SCHEMBL30737420 | 0.84 | LMNA (0.43) | LMNAL3MBTL1OPRM1OPRD1OPRK1 | |
| SCHEMBL30737193 | 0.83 | LMNA (0.51) | LMNAL3MBTL1MAPK1KDM4EGRN | |
| SCHEMBL27234556 | 0.82 | LMNA (0.42) | LMNAL3MBTL1OPRM1OPRD1OPRK1 | |
| SCHEMBL693093 | 0.82 | HRH3 (0.59) | LMNAL3MBTL1MAPK1KDM4EALDH1A1 | |
| SCHEMBL31646829 | 0.82 | L3MBTL1 (0.54) | LMNAL3MBTL1MAPK1KDM4EALDH1A1 | |
| SCHEMBL31646216 | 0.81 | MAPT (0.50) | LMNAL3MBTL1MAPK1KDM4EGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NEUROPN THERAPEUTICS (US) | 2024-06-04 | — | — | US | disclosed |
| US-7858646-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858646-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| EP-1817300-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | ARRAY BIOPHARMA, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | ARRAY BIOPHARMA, INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | HTR7, UGT2B7, HK1 | LMNA 1369/4885L3MBTL1 4392/4885TSHR 1992/4885 |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, HPGDS | LMNA 2951/4885L3MBTL1 4672/4885TSHR 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.